Among the world's top 3 Active Pharmaceutical Ingredient (API) manufacturers, serving 100+ countries
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 53 | 53 | 53 | 53 | 53 | 53 | 53 | 53 |
| Reserves | 7.3k | 9.2k | 11.6k | 12.7k | 13.4k | 14.8k | 15.4k | 16.7k |
| Borrowings | 34 | 0 | 0 | 0 | 0 | 2 | 90 | 0 |
| Other Liabilities | 1.2k | 1.5k | 1.6k | 1.6k | 1.9k | 1.9k | 2.6k | 3.2k |
| Total Liabilities | 8.5k | 10.7k | 13.3k | 14.4k | 15.4k | 16.8k | 18.2k | 20.0k |
| AssetsFixed Assets | 2.8k | 3.7k | 4.3k | 4.7k | 4.7k | 5.4k | 5.7k | 6.5k |
| CWIP | 920 | 711 | 470 | 212 | 778 | 1.0k | 2.0k | 2.1k |
| Investments | 979 | 7 | 79 | 84 | 89 | 72 | 67 | 76 |
| Other Assets | 3.8k | 6.3k | 8.4k | 9.3k | 9.8k | 10.3k | 10.4k | 11.2k |
| Total Assets | 8.5k | 10.7k | 13.3k | 14.4k | 15.4k | 16.8k | 18.2k | 20.0k |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 964 | 1.2k | 1.9k | 1.9k | 2.4k | 1.3k | 1.6k | 2.7k |
| Cash from Investing | -684 | -81 | 75 | -2.2k | -2.7k | -268 | -803 | -2.2k |
| Cash from Financing | -246 | -1.1k | -34 | -532 | -796 | -798 | -797 | -802 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 231 | 26 | 1.0k | 1.2k | 2.0k | 264 | 213 | 195 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (69.4×) and current (68.7×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 12.7% growth and a 69× exit, ₹6743 only delivers your return if you pay ₹5,369. The price is currently baking in 17% growth.
EPS grows 12.7%/yr for 5 years, then fades to 6% over 2, exits at 69×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 12.7% | 110.68 |
| FY28 | 12.7% | 124.74 |
| FY29 | 12.7% | 140.58 |
| FY30 | 12.7% | 158.44 |
| FY31 | 12.7% | 178.56 |
| FY32 | 9.3% ·fade | 195.25 |
| FY33 | 6.0% ·fade | 206.97 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.